World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments

April 2009 | 80 pages | ID: W0D3C253FF1EN
Renub Research

Abstracts

World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments published by Renub Research talks about the world vaccine market. This report gives the past, present scenario on the vaccines market and also forecast on future of vaccines market. Such as market size of Hepatitis B vaccines, Pneumococcal vaccines, Cervical Cancer vaccines etc. are there in the report. Forecast for the future market size of vaccine for diseases like Malaria, Ebola, Tuberculosis (TB), Japanese Encephalitis, West Nile, Typhoid etc. which are yet to be launched in the market have also been included in the report. The report also forecast on the sales of the key vaccines brands like Gardasil, Fluzone/Vaxigrip/Mutagrip, Prevnar, RotaTeq, Rotarix etc. Major companies’ vaccines sales data for the year 2007 and 2008 are also there in the report.

Market Overview

The vaccines landscape is very different now as compared to few years back. With increasing public awareness about preventive healthcare and increased spending by governments for the same has once again put spotlight on the vaccines. Quality of life is expected to increase markedly with introduction of newer vaccines covering more and more diseases. Due to this vaccines, which were perceived as low margin business before, have now emerged as one of the most lucrative segments in the pharmaceutical industry. Moreover with the success of a number of blockbuster products, the market place has changed dramatically. Pharma major’s today look upon vaccines as a driver for their future growth.

Already vaccines have become big business for pharmaceutical giants like GlaxoSmithKline, sanofi pasteur and Merck & Co.. For e.g. GSK Bio, GSK's vaccines arm, accounted for 8.4 percent of GSK's pharmaceutical turnover in 2006. And it is expected that by 2012 companies like GSK, Sanofi-aventis, Merck & Co., and Wyeth vaccines arm will fetch them more than 10 percent of sales from vaccine as a percentage of overall pharma sales.

Sector wise basic pediatrics share is declining as most of the vaccines in this sector are either off patent or newer and more effective vaccines have replaced them. Proprietary pediatrics and cancer pediatrics will define the future growth going forward. Vaccines like Prevnar (Pneumococcal vaccines), Gardasil (Cervical cancer vaccines) have crossed the sales of US$ 1 Billion by 2007. In fact Prevnar became the first vaccine to cross the US$ 2 Billion annual sales in 2007.

With the growth in international travel vaccine market of adult/travel sector is also going to grow further. Malaria vaccines, Typhoid Vaccines and Japanese Encephalitis Vaccines are expected to grow further in the market. Malaria vaccine which is expected to launch in 2010 or 2011, is forecasted to be worth US$ 419 Million market by 2025. Typhoid vaccine market for travelers is expected to grow with a CAGR of 4 percent from 2003 to 2014.

Ongoing spate of mergers and accquisition in pharma sector its effect and causes on the overall industry. Such as Pfizer taking over Wyeth would cement Pfizer’s position as the world’s leading drugmaker. Geographic segment wise China and India vaccine market will grow considerably in future and Japanese vaccine market has also started to open up further from regulatory and political barriers. Overall the worldwide vaccine market has registered revenue of US$ 21 Billion in 2008.

Report Forecast

• Worldwide Vaccine Market
• Influenza Market
• Adult/Travel Market
• Proprietary Pediatrics/Adolescent Market
• Enhanced Pediatrics Market
• Basic Pediatrics Market
• Major Vaccines Market (For complete list see heading no. 4 below in table of contents)
• Major Geographic Vaccine Markets
• Sales Forecast for Key Vaccine Brands (Cervarix, RotaTeq, Flu, Zostavax, ProQuad, Infanrix (DTP), Menactra, Rotarix, Gardasil, Prevnar, Fluzone/Vaxigrip/Mutagrip, 13-Valent Pneumococcal, Synflorix, Imvamune, H5N1 Influenza Vaccine, Hepatitis B vaccine).

Research Highlights

• M&A by big pharma like Pfizer and Merck and its effect in terms of consolidation in pharma industry.
• Collectively Europe & Asia Pacific accounts for the 60 percent of the Hepatitis B vaccine market.
• Public market share of malaria vaccine revenue increases from 43 percent in 2015 to 77 percent in 2025.
• Japanese encephalitis vaccine market is expected to cross the figure of US$ 400 Million by 2012.
• By 2015 it is expected that Cervical Cancer patients will be 320 Thousand worldwide.
• India and China vaccine market is expected to grow with a CAGR of 16 and 17.8 percent respectively from 2006 to 2013.
• Vaccines like Infanrix (DTP) of GSK and Flu vaccine of sanofi pasteur will have a market of more than US$ 1 Billion by 2010.
• Despite global slowdown vaccine sale of all major companies such as Merck, GSK, Sanofi Aventis has been increased in 2008 compared to 2007.
• 14 different vaccines have been analyzed in the report (for details refer heading no. 4 below in table of contents).

Data Sources

The information and data in this report has been collected from various printable and non-pintable sources like Magazines, Newspapers, Trade Journals, White papers, Online paid databases, News websites Government Agencies and Trade associations.

Contents

1. EXECUTIVE SUMMARY

2. VACCINES MARKET - WHY IS IT SO ATTRACTIVE

2.1 Big Pharma Upping Their Commitment to Vaccines
2.2 Vaccine 'Outsiders' Jumping Onto Bandwagon (Acquisitions by Big Pharma Players)
2.3 Several New Vaccines, Many with Blockbuster Potential

3. WORLDWIDE VACCINE MARKET

3.1 By Sector – Vaccine Market
  3.1.1 Influenza
  3.1.2 Adult/Travel
  3.1.3 Proprietary Pediatrics/Adolescent
  3.1.4 Enhanced Pediatrics
  3.1.5 Basic Pediatrics

4. MAJOR VACCINE CASES, MARKET SIZES & FUTURE FORECAST

4.1 Pneumococcal Vaccines
  4.1.1 Market Size of Pneumococcal Vaccines & Future Forecast
4.2 Polio Vaccines
  4.2.1 Number of Polio Cases (in 42 Countries)
  4.2.2 Market Size of Polio Vaccines & Future Forecast
4.3 Meningitis Vaccines
  4.3.1 Number of Meningitis Cases
  4.3.2 Market Size of Meningitis Vaccines & Future Forecast
4.4 Rotavirus Vaccines
  4.4.1 Number of Rotavirus Cases (in 27 Countries)
  4.4.2 Market Size of Rotavirus Vaccines & Future Forecast
4.5 Tuberculosis (TB) Vaccines
  4.5.1 Number of Tuberculosis Cases
  4.5.2 Market Size of Tuberculosis Vaccines & Future Forecast
4.6 Measles, Mumps & Rubella (MMR) Vaccines
  4.6.1 Number of Measles, Mumps & Rubella Cases
4.7 DTP Vaccines
  4.7.1 Number of Diphtheria, Pertussis and Tetanus Cases
  4.7.2 Market Size of DTP Vaccines
4.8 Hepatitis B Vaccines
  4.8.1 Percent of Hepatitis B Vaccine Immunization
  4.8.2 Market Size of Hepatitis B Vaccines & Future Forecast
4.9 Malaria Vaccines
  4.9.1 Number of Malaria Cases
  4.9.2 Market Size of Malaria Vaccines Market Future Forecast
4.10 Japanese Encephalitis Vaccines
  4.10.1 Number of Japanese Encephalitis Cases
  4.10.2 Market Size of Japanese Encephalitis Vaccines & Future Forecast
4.11 West Nile Vaccines
  4.11.1 Number of West Nile Cases
  4.11.2 Market Size of West Nile Vaccines & Future Forecast
4.12 Ebola Vaccines
  4.12.1 Number of Ebola Cases
  4.12.2 Market Size of Ebola Vaccines & Future Forecast
4.13 Cervical Cancer Vaccines
  4.13.1 Number of Cancer & Cervical Cancer Cases
  4.13.2 Market Size of Cervical Cancer Vaccines & Future Forecast
4.14 Typhoid Vaccines
  4.14.1 Number of Typhoid Cases
  4.14.2 Market Size of Typhoid Vaccines & Future Forecast

5. MAJOR GEOGRAPHIC MARKETS

5.1 India Vaccine Market
5.2 China Vaccine Market
5.3 Japan Vaccine Market
5.4 US Vaccine Market

6. COMPETITIVE LANDSCAPE

6.1 Worldwide – 5 Major Companies Forecast of Vaccine Sales as Percentage of Overall Pharma Sales
6.2 Worldwide – Sales Forecast for Key Vaccine Brands
6.3 Global Economic Crisis - Increase in Vaccine Sales

List Of Figures

LIST OF FIGURES:

Figure 2 1: Worldwide – Vaccines: GSK, Merck & Co., Novartis & Sanofi-aventis - Sales as a Percentage of Overall Pharma Sales (in Percent), 2006
Figure 3 1: Worldwide – Vaccine Market (in Billion US$), 2007 - 2013
Figure 3 2: Worldwide – Influenza Vaccine Market (in Million US$), 2004 – 2008
Figure 3 3: Worldwide – Forecast for Influenza Vaccine Market (in Million US$), 2009 – 2013
Figure 3 4: Worldwide – Adult/Travel Vaccine Market (in Million US$), 2004 – 2008
Figure 3 5: Worldwide – Forecast for Adult/Travel Vaccine Market (in Million US$), 2009 – 2013
Figure 3 6: Worldwide - Proprietary Pediatrics/Adolescent Vaccine Market (in Million US$), 2004 – 2008
Figure 3 7: Worldwide - Forecast for Proprietary Pediatrics/Adolescent Vaccine Market (in Million US$), 2009 – 2013
Figure 3 8: Worldwide - Enhanced Pediatrics Vaccine Market (in Million US$), 2004 – 2008
Figure 3 9: Worldwide - Forecast for Enhanced Pediatrics Vaccine Market (in Million US$), 2009 – 2013
Figure 3 10: Worldwide - Basic Pediatrics Vaccine Market (in Million US$), 2004 – 2008
Figure 3 11: Worldwide - Forecast for Basic Pediatrics Vaccine Market (in Million US$), 2009 – 2013
Figure 4 1: Worldwide - Pneumococcal Vaccine Pipeline
Figure 4 2: Worldwide - Pneumococcal Vaccine Market (in Billion US$), 2004 - 2007 & 2018F
Figure 4 3: Worldwide – Forecast for Global Funds for Immunization in Pneumococcal Vaccine Market (in Billion US$ & Percent), 2018
Figure 4 4: Worldwide - Number of Polio Virus Cases, 2000 – March 2009
Figure 4 6: Africa – Number of Meningitis Cases (in Number), 2001 – 2007
Figure 4 7: Worldwide - Meningitis Vaccine Market (in Billion US$), 2004 & 2010F
Figure 4 8: Worldwide - Forecast for Rotavirus Vaccine Market (in Billion US$), 2010
Figure 4 9: Worldwide – By Geographic Region Number of Tuberculosis Cases (in Thousand), 2006
Figure 4 10: Worldwide – Distribution of Tuberculosis Patients in Previous Cases, New Smear-positive Cases & HIV-positive Cases (in Million & Percent), 2006
Figure 4 11: Worldwide – Forecast for TB BCG-Replacement Vaccine (in US$ Million), 2013 – 2030
Figure 4 12: Worldwide – Forecast for TB Booster Vaccine (in US$ Million), 2013 -2030
Figure 4 13: Worldwide – Forecast for TB Prime-Boost Strategy (in US$ Million), 2013 – 2030
Figure 4 14: Worldwide – By Player Share of DTP Combos Market (in Million & Percent), 2004
Figure 4 15: Worldwide – By Region Hepatitis B Vaccine Immunization Coverage (in Percent), 2007
Figure 4 16: Worldwide - Hepatitis B Vaccine Market (in Billion US$), 2005 - 2010F
Figure 4 17: Worldwide – Combined Hepatitis B Vaccine Market of Europe & Asia Pacific Region (in Billion & Percent US$), 2006
Figure 4 18: Worldwide – Forecast for Malaria Vaccine Market (in Million US$), 2010 – 2025
Figure 4 19: Worldwide – Forecast for Military Market for Malaria Vaccine (in Million US$), 2010 – 2025
Figure 4 20: Worldwide – Forecast for Private Market for Malaria Vaccine (in Million US$), 2010 – 2025
Figure 4 21: Worldwide – Forecast for Public Market for Malaria Vaccine (in Million US$), 2010 – 2025
Figure 4 22: Worldwide - Japanese Encephalitis Vaccine Market (in Million US$), 2004 – 2007
Figure 4 23: Worldwide – Forecast for Japanese Encephalitis Vaccine Market (in Million US$), 2008 – 2012
Figure 4 24: Worldwide – Japanese Encephalitis Vaccine Market Growth (in Percent), 2004 – 2012F
Figure 4 25: US – Number of West Nile Virus Cases & Deaths (in Numbers), Since 1999
Figure 4 26: Worldwide – Forecast for West Nile Vaccines Market (in Million US$), 2010
Figure 4 27: Worldwide – Number of Ebola Cases & Deaths (in Numbers)
Figure 4 28: Worldwide & US – Forecast of Ebola Vaccines Market (in Million US$), 2011
Figure 4 29: Worldwide – Forecast for Cervical Cancer Cases (in Numbers), 2015 & 2030
Figure 4 30: Worldwide - Cervical Cancer Vaccines Market (in Billion US$), 2007 – 2010F
Figure 4 31: Worldwide - Number of Typhoid Cases (in Million) Every Year
Figure 4 32: Worldwide – Travelers Market for Typhoid Vaccine (in Million US$), 2003 & 2014F
Figure 5 1: India – Vaccine Market (in Million US$), 2006 – 2013F
Figure 5 2: India – Share of Pediatric Vaccine Market & Adult/Travel & Therapeutic Market (in Million US$ & Percent), 2006-07
Figure 5 3: China – Vaccine Market (in Million US$), 2006 – 2013F
Figure 5 4: China – Market Share of Chinese & Foreigner Drug Manufacturer in Vaccine (in US$ Million & Percent), 2006
Figure 5 5: Japan – Vaccine Market (in Million US$), 2008 & 2016F
Figure 5 6: US – Vaccine Market (in Billion US$), 2003 & 2008E

List Of Tables

LIST OF TABLES:

Table 2 1: Worldwide – 15 Major Acquisitions in Pharmaceuticals (in Billion US$), 2005 – 2009
Table 2 2: Worldwide – 16 Major Acquisitions in Biotechnology (in Billion US$), 2005 – 2009
Table 2 3: Worldwide – Vaccines Market: Prevnar, Gardasil, Engerix-B, Havrix, Twinrix, Infanrix, Pediarix, Fluzone, and IPOL, Hib, Petrussis – Sales (in Billion US$), 2006 - 2008
Table 4 1: Worldwide – Top 42 Countries with Maximum Number of Polio Cases, 2000 – March 2009
Table 4 2: Worldwide – 27 Countries with Number of Diarrhea Hospitalizations Cases and Rotavirus Cases (in Number & Percent), 2000–2004
Table 4 3: Worldwide – By Geographic Region Number of Measles Cases, 2000 - 2007
Table 4 4: Worldwide – By Geographic Region Number of Mumps Cases, 2000 – 2007
Table 4 5: Worldwide – By Geographic Region Number of Rubella Cases, 2000 – 2007
Table 4 6: Worldwide – By Geographic Region Number of Diphtheria Cases, 2000 – 2007
Table 4 7: Worldwide – By Geographic Region Number of Pertussis Cases, 2000 – 2007
Table 4 8: Worldwide – By Geographic Region Number of Tetanus Cases, 2000 – 2007
Table 4 9: Worldwide – By Geographic Region Number of Malaria Cases, 2004 – 2006
Table 4 10: Worldwide – By Geographic Region Number of Japanese Encephalitis Cases, 2006 & 2007
Table 4 11: Worldwide – By Geographic Region Estimated Cancer Patients (in Numbers), 2007
Table 5 1: China - Vaccine Classification
Table 6 1: Worldwide – Forecast for Vaccines: GSK, Merck & Co., Novartis, Sanofi-aventis & Wyeth - Sales as a Percentage of Overall Pharma Sales (in Percent), 2009 – 2012
Table 6 2: Worldwide – Sales Forecast for Vaccines Market: Cervarix, RotaTeq, Flu, Zostavax, ProQuad, Infanrix (DTP), Menactra, Rotarix (in Million US$), 2010
Table 6 3: Worldwide – Revenues of Vaccine Brands: Gardasil, Prevnar, Fluzone/Vaxigrip/Mutagrip, RotaTeq (in Million US$) 2007 & 2012F
Table 6 4: Worldwide – Revenue Forecast of Vaccine Brands: 13-Valent Pneumococcal, Synflorix, Imvamune, H5N1 Influenza Vaccine, Hepatitis B vaccine (in Million US$), 2012
Table 6 5: Worldwide – Vaccine Sales of Companies: Merck, GSK, Sanofi Aventis, Wyeth, Novartis, Sanofi Merck Pasteur, Baxter, Crucell, Saloy Mitsubishi-Tanable (in US$ Billion), 2007 & 2008